Clinical Trials
200 trialsComparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
PERM
Royal Marsden NHS Foundation Trust
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Tamarack
MacroGenics
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Sanofi
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
RELATIVITY-098
Bristol-Myers Squibb
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Pembrolizumab and EDP1503 in Advanced Melanoma
University of Chicago
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
PAVO
Tempus AI
MAVIS
Polynoma LLC
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
COMBI-i
Novartis
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
MGC018 With or Without MGA012 in Advanced Solid Tumors
MacroGenics
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Herlev Hospital
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
University of California, San Diego
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
ImmunoGenesis
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
ATL001 in Patients With Metastatic or Recurrent Melanoma
Achilles Therapeutics UK Limited
PANAMA
Karyopharm Therapeutics Inc
MODULATE
Immodulon Therapeutics Ltd
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
Astellas Pharma Inc
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
Wake Forest University Health Sciences
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
Hoosier Cancer Research Network
PVSRIPO for Patients With Unresectable Melanoma
Istari Oncology, Inc.
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Providence Health & Services
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Karyopharm Therapeutics Inc
V937-011
Merck Sharp & Dohme LLC
JAVELIN Medley
Pfizer
IL-2
Nova Scotia Health Authority
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Haihe Biopharma Co., Ltd.
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.